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12th
Cirrhosis and Chronic Liver Disease is the 12th leading cause of death in the 
United States
Introduction:
● Cirrhosis is a heterogeneous disease of late stage progressive hepatic fibrosis
● It is often an indolent disease
○ Often is discovered during a routine examination with laboratory or radiographic studies, or at 
autopsy
○ Most patients remain asymptomatic until “decompensation”
○ Unfortunately, at that point, largely irreversible and poor prognosis
● Preventive strategies can maximize time before liver transplantation or death for 
those with early cirrhosis by avoiding further damage and mitigating comorbidity 
Role as Primary Care Physicians...
● The incidence of liver cirrhosis is expected to increase in the near future
● PCPs play a key role in prevention, treatment, timely referrals to specialists and 
multidisciplinary team members (dieticians, psychologists, etc.), collaborative 
management, surveillance and home care of populations at risk!
Algorithm for the management of patients with (or with 
suspected) liver cirrhosis in General Practice
Objectives:
● Understand the morbidity and mortality associated with Cirrhosis in the United 
States
● Recognize etiologies and clinical presentation of cirrhosis
● Identify decompensated cirrhosis and approaches to treatment and monitoring
Agenda:
● Definition and Epidemiology
● Etiologies
● Clinical Presentation
● Diagnosis and Evaluation/Classification
● Management of Compensated Cirrhosis












Hepatic parenchymal necrosis and an inflammatory response to the underlying cause 
→ chronic hepatocellular injury 
→ subsequent hepatic repair mechanisms lead to irreversible fibrosis and 
abnormal tissue architecture (nodular regeneration)
→ which ultimate results in impaired liver function
Impact of Liver 
Disease in the 
US
Number of adults with diagnosed liver 
disease: 4.5 million
Percent of adults with diagnosed liver 
disease: 1.8%
Deaths per 100,000 population: 12.8
More common in adults ages 45-54
Epidemiology of Cirrhosis:
Prevalence: approx. 0.27%* in U.S. adults 
Sex: ♂ > ♀ (2:1)
Responsible for approx. 1–2% of all deaths in the United States; most deaths occurring 




Health Disparities related to Cirrhosis:
● Highest prevalence among non-Hispanic Blacks, Mexican Americans, those living 
below the poverty level, and those with less than a 12th grade education
● Additionally, there are disparities associated with referral to transplant centers and 
receipt of donor organs
● Public health efforts are needed to reduce this disease burden, particularly among 
racial/ethnic minorities and individuals at lower socioeconomic status
Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin 
Gastroenterol. 2015; 49(8): 690-696.
Costs to the Healthcare System:
● Cirrhosis and advanced liver disease cost the United States between $12 billion and 
$23 billion dollars in health care expenses annually
● Additionally, annual costs increase with decompensation; for instance:
○ $2,400 for the treatment of diuretic-sensitive ascites
○ $24,800 for the treatment of diuretic-refractory ascites
○ $25,600 for the treatment of variceal hemorrhage
○ $16,400 for the treatment of hepatic encephalopathy
○ $44,200 for the treatment of hepatocellular carcinoma.










Name all of the main clinical features 
of cirrhosis of the liver.

Clinical Presentation
Common cutaneous manifestations of cirrhosis




● May be normal!
● Incidentally noted elevated liver enzymes (AST, ALT, bilirubin)
● Low albumin (<3.5g/dL)
● Thrombocytopenia (<160K) 
● Prolonged Prothrombin Time (PT)/Elevated INR
Other labs to order include: Alkaline Phosphatase, Gamma-glutamyl transferase, viral 
hepatitis serologies, ferritin, transferrin saturation, fasting lipid and a1c (if risk factors 
for NAFLD exist), consider studies for autoimmune hepatitis, ANA, Anti-SMAb, or others 




● Biomarkers (e.g. FibroSure) and non-proprietary, serum based calculators (e.g. AST 
to platelet ratio index [APRI], NAFLD fibrosis score, etc.)
● Ultrasonography
○ Low cost, easily accessible
○ Sensitive and specific for steatosis, but may miss fibrosis and cirrhosis (only 40-57% sensitive)
U/S: advanced cirrhotic liver appears to 
be nodular, irregular, and contracted with 
relatively enlarged caudate lobe (C) and 
lateral segment (L) of the left lobe. Fatty 
infiltration and fibrosis give a coarse 
echotexture of the liver parenchyma.
Transient Elastography:
Transient Elasticity
● Now more widely available; only takes 5 minutes!
● Rapidly replacing biopsy as preferred method for fibrosis 
staging
● U/S technique performed w/ specialized machine (Fibro-Scan) 
to determine liver stiffness by measuring velocity of 
low-frequency elastic shear waves propagating through the 
liver
● 81% sensitive and 88% specific for detecting liver fibrosis and 
cirrhosis
● Less accurate at distinguishing between stages of liver disease
● Less reliable in patients w/ obesity, ascites, excessive EtOH 
intake, extrahepatic cholestasis, acute hepatic inflammation
Liver Biopsy Indications:
● Concern for fibrosis remains after indeterminate or conflicting clinical, lab and 
imaging results
● Transient Elastography is not suitable
● To clarify etiology of disease after inconclusive noninvasive evaluation
Still the reference standard in diagnosing cirrhosis, however a 20% error rate still occurs 






Points 1 2 3
Serum albumin g/dL > 3.5 2.8–3.5 < 2.8
Serum bilirubin mg/dL < 2.0 2.0–3.0 > 3.0
INR < 1.7 1.7–2.3 > 2.3
Ascites None Mild Moderate
Hepatic encephalopathy None Minimal Advanced
Child-Pugh class A: 5–6 points; Child-Pugh class B: 7–9 points; Child-Pugh class C: 10–15 points
Management and Treating 
Complications...
Management and Prevention of 
Complications:
● primary goals are to prevent cirrhosis complications, liver decompensation, and 
death
● accomplished with rigorous prevention counseling (see next slide), monitoring, 









● Refer for liver transplantation evaluation if:







● PH is the initial and main consequence of cirrhosis and is responsible for the majority of its 
complications.
● Hepatic Venous Pressure Gradient (HVPG) is the gold standard for assessing severity of PH. 
It’s an estimate of the pressure differential between the portal vein and IVC.
Varices:
● Portal hypertension predisposes patients with cirrhosis to develop esophageal 
varices
○ Gastroesophageal varices (GEV) are present in approximately 50% of patients with cirrhosis, but this 
depends on the clinical stage.
■ In patients with compensated cirrhosis, GEV are present in 30%-40%, whereas they can be 
present in up to 85% of patients with decompensated cirrhosis
○ Patients with varices have a one in three chance of developing a variceal bleed in the two years after 
diagnosis, with a 20% to 40% mortality rate per episode.
● Endoscopy is the preferred screening method for esophageal varices
○ Many experts and guidelines recommend screening all patients with cirrhosis; however, newer 
recommendations suggest targeted screening of patients with clinically significant portal 
hypertension.
○ Every 1-2 years if small varices found and every 2-3 years if no varices found
Variceal Hemorrhage
● Occurance rate of variceal hemorrhage varies depending on the severity of the liver 
disease, size of varices, and presence of variceal wall thinning (red wale marks)
○ ~10-15% per year
● Six-week mortality (the now-recognized primary endpoint to assess impact of 
therapies for acute hemorrhage) ranges between 15-25%!
Management of Varices and Variceal 
Hemorrhage
● Primary Prophylaxis (see next slide)
● If bleeding, acute treatment goals include:
○ hemodynamic resuscitation
○ treatment of active bleeding
○ prevention of rebleeding
■ Band ligation is the standard for the control of variceal bleeding. 
■ If banding is difficult because of continued variceal bleeding, endoscopic sclerotherapy with 
vasoconstrictors (e.g., octreotide) or a Sengstaken-Blakemore tube insertion (with adequate 
airway protection) may be used until TIPS or surgical treatment can be arranged.
● Recurrent or Treatment Resistant Hemorrhage:
○ Pursue TIPS (transjugular intrahepatic portosystemic shunt) to lower portal pressure






● A needle catheter inserted via the internal jugular vein → passed along to hepatic 
vein → pierced through liver parenchyma to intrahepatic branch of the portal vein → 
expandable metal stent is placed → side-to-side portocaval shunt
● Assures blood drainage from the portal to the systemic system bypassing the liver, 
thus lowering portal pressure
Several contraindications...
Ascites:
● Abnormal accumulation of fluid in the peritoneal cavity
○ Ddx includes conditions causing portal hypertension and/or hypoalbuminemia
● If ascites origin in unclear, can perform paracentesis and ascitic fluid assessment
Treating Ascites in Cirrhosis:
● Sodium Restriction!
○ MAX 2000mg DAILY
● Spironolactone
● Furosemide (if massive ascites)
● Albumin
○ Administer if > 5L fluid removed during paracentesis
● Fluid Restriction?
○ If serum sodium is less than 125 mEq per L
Need to monitor potassium and creatinine
If refractory or diuretics contraindicated → large volume paracentesis and 
consideration of TIPS
Spontaneous Bacterial Peritonitis:
● Infx of peritoneal fluid. A common complication of uncontrolled ascites
○ Caused by translocation of gut bacteria or sepsis
● Presentation: signs of peritonitis, SIRS, worsening liver fx, hepatic encephalopathy, 
renal failure, shock, GI bleed…However, may be asymptomatic
● Diagnosed by PMN >250/mm³ or + Gram stain/culture on ascitic fluid
● Historically, HIGH MORTALITY (related to renal failure); reduced to ~ 20% with early 
diagnosis & treatment
Treatment for SBP
Start empiric tx (e.g. cefoxitime) and use ascitic culture to guide therapy, however pt’s 
may have culture-negative SBP
- May use ciprofloxacin unable to use cephalosporin
- Consideration of resistance patterns (e.g. if pt on fluoroquinolone for ppx)
Most cases of SBP are due to gut bacteria such as E. coli and Klebsiella, though 
streptococcal and staphylococcal infections can also occur
Albumin should be administered from day 1-3 of treatment if Cr>1, BUN >30, tBili >4 to 
reduce risk of renal failure
d/c bb once SBP has developed (associated w/ increased mortality)
SBP - prophylactic antibiotics?
Clinical Question: 
Should antibiotic prophylaxis be used for hospitalized patients with cirrhosis and upper 
gastrointestinal bleeding? 
Evidence-Based Answer:
Antibiotics should be used for prophylaxis in hospitalized patients with cirrhosis and 
upper gastrointestinal bleeding. (Strength of Recommendation: A, based on consistent 
results from two meta-analyses and a cohort study.) 
Prophylaxis reduces all-cause mortality by 21%, as well as bacterial infections and 
rebleeding.
Hepatorenal Syndrome:
● Renal dysfunction secondary to reduction in renal blood flow in the setting of 
cirrhosis and portal hypertension
● Mainstay of treatment is vasopressor therapy with albumin
○ Attempt to reverse splanchnic vasodilation and improve renal blood flow
○ Primarily terlipressin and noradrenalin
● Limited role for Renal replacement therapy or TIPS
● Leads to death in the absence of liver transplantation :( 

RI = resistive indices
Hepatic Encephalopathy:
● Brain dysfunction caused by liver insufficiency and failure to detoxify NH3
● Wide spectrum of neurologic/ psychiatric abnormalities from mild cognitive loss to 
confusion to coma
○ Onset may be gradual or sudden
○ May include movement problems, changes in mood, confusion, disordered sleep, or changes in 
personality
● Pitfalls: High blood ammonia levels alone add no diagnostic, staging, or prognostic 




Treatment options for Hepatic 
Encephalopathy
Other Complications of Cirrhosis
● bone diseases, such as Osteoporosis
● Biliary disease and Gallstones
● Malabsorption and Malnutrition
● Bruising and Bleeding easily 
● Sensitivity to Medicines (limited drug metabolism)
● Insulin resistance and Type 2 diabetes

Secondary Prevention
Preventing Superimposed Liver Insults:






Careful dietary counseling and encouragement 
of weight loss is vital to reducing mortality
Dietary Counseling
Surveillance
Assess Cirrhosis Patients for Hepatocellular Carcinoma:
- AASLD recommends U/S + α‐fetoprotein every 6-12 months
- Data is currently lacking**
Monitoring for patients with Varices:
- Upper Endoscopy every 1-2 years
- Newer guidelines suggest targeted screening for esophageal varices in patients 
with clinically significant portal hypertension rather than screening all patients 
with cirrhosis
Liver Transplantation
● Organ transplantation 
has become standard of 
care for patients with 
end-stage liver, kidney, 
lung and heart disease 
● Liver is the second most 
commonly transplanted 
organ





● Liver cirrhosis has an increasing prevalence worldwide, which matches the 
increase in viral hepatitis infection and metabolic steatohepatitis
● Liver transplantation is standard of care for end stage liver disease, however access 
is limited
● PCP’s role in prevention, surveillance, and secondary prevention to reduce 
decompensation are vital to reducing morbidity and mortality from chronic liver 
disease
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